Koers Celladon Corp Nasdaq
Aandelen
US15117E1073
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 25,22 mln. 23,43 mln. | Omzet 2025 * | 32,65 mln. 30,35 mln. | Marktkapitalisatie | 3,98 mln. 3,7 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -24 mln. -22,3 mln. | Nettowinst (verlies) 2025 * | -9 mln. -8,36 mln. | EV/omzet 2024 * | 0,16 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 0,12 x |
K/w-verhouding 2024 * |
-0,17
x | K/w-verhouding 2025 * |
-0,75
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 85,23% |
Recentste transcriptie over Celladon Corp
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Apelian
CEO | Chief Executive Officer | 59 | 14-06-17 |
James Vollins
CMP | Compliance Officer | 55 | 13-04-23 |
Colin Hislop
CTO | Chief Tech/Sci/R&D Officer | 66 | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 57 | 18-07-22 | |
Thomas Dietz
CHM | Chairman | 60 | 22-03-16 |
David Apelian
CEO | Chief Executive Officer | 59 | 14-06-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,69% | 47,9 mld. | |
+46,90% | 41,42 mld. | |
-3,46% | 40,7 mld. | |
-6,20% | 28,92 mld. | |
+9,17% | 25,55 mld. | |
-20,42% | 19,27 mld. | |
+0,17% | 12,15 mld. | |
+28,07% | 12,14 mld. | |
-1,24% | 11,99 mld. |